Stocks and Investing Stocks and Investing
Fri, September 20, 2024
Thu, September 19, 2024
Wed, September 18, 2024
Tue, September 17, 2024

David Lebowitz Maintained (ASND) at Strong Buy with Increased Target to $207 on, Sep 17th, 2024


Published on 2024-10-28 14:18:43 - WOPRAI, David Lebowitz
  Print publication without navigation


David Lebowitz of Citigroup, Maintained "Ascendis Pharma A/S" (ASND) at Strong Buy with Increased Target from $178 to $207 on, Sep 17th, 2024.

David has made no other calls on ASND in the last 4 months.



There are 6 other peers that have a rating on ASND. Out of the 6 peers that are also analyzing ASND, 0 agree with David's Rating of Hold.



These are the ratings of the 6 analyists that currently disagree with David


  • Li Watsek of "Cantor Fitzgerald" Reiterated at Buy and Held Target at $170 on, Monday, September 16th, 2024
  • Tazeen Ahmad of "B of A Securities" Maintained at Strong Buy with Increased Target to $175 on, Wednesday, September 4th, 2024
  • Yaron Werber of "TD Cowen" Maintained at Strong Buy with Decreased Target to $157 on, Wednesday, September 4th, 2024
  • Jessica Fye of "JP Morgan" Maintained at Buy with Decreased Target to $165 on, Wednesday, September 4th, 2024
  • Kelly Shi of "Jefferies" Maintained at Strong Buy with Increased Target to $196 on, Tuesday, August 13th, 2024
  • Alex Thompson of "Stifel" Initiated at Strong Buy and Held Target at $200 on, Friday, May 31st, 2024